Trial
NCT07223567
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Bayer; MacroGenics
Condition
Rectal Cancer
Intervention
Regorafenib
Why stopped
0 participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-25